Science
Mario Balsa: No Association Between Anti–PD-1 Infusion Timing and Survival
Mario Balsa/ LinkedIn

Mario Balsa: No Association Between Anti–PD-1 Infusion Timing and Survival

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared on X:

“Does the timing of anti–PD-1 infusions matter? (NCI/SWOG S1404, n=628)

No association between earlier infusion time and RFS or OS after bias-adjusted analyses

Time-dependent multivariable models failed to confirm any survival benefit

Distance to the treatment center influenced infusion timing, highlighting an important confounder

Maybe the clock wasn’t ticking in favor of IO…just in favor of bias! ”

Mario Balsa

Title: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy

Authors: Megan Othus, Thach-Giao Truong, Elad Sharon, Kari Kendra, Kenneth Grossmann, Elizabeth Buchbinder, Nikhil I. Khushalani, Zeynep Eroglu, Sunandana Chandra, Gary C. Doolittle, John M. Kirkwood, Alexandra Ikeguchi, Catalin Mihalcioiu, C. Lance Cowey, Sunil A. Reddy, Douglas B. Johnson, Matthew Taylor, Vernon K. Sondak, Antoni Ribas, Sapna P. Patel

Read the article.

Mario Balsa

Other articles about Resectable Melanoma on OncoDaily.

Alexandra Ikeguchi Antoni Ribas C. Lance Cowey cancer Cancer research Catalin Mihalcioiu Douglas B Johnson Elad Sharon Elizabeth Buchbinder Gary C Doolittle High-Risk Resectable Melanoma John M. Kirkwood Kari Kendra Kenneth Grossmann Mario Balsa Matthew Taylor Megan Othus Melanoma NCI/SWOG Nikhil I. Khushalani OncoDaily Oncology resectable melanoma S1404 Sapna P Patel Sunandana Chandra Sunil A. Reddy Thach Giao Truong Vernon K Sondak Zeynep Eroglu